Aadi Bioscience (FRA:3350) Total Liabilities : €18.96 Mil (As of Mar. 2024)

View and export this data going back to 2021. Start your Free Trial

What is Aadi Bioscience Total Liabilities?

Aadi Bioscience's Total Liabilities for the quarter that ended in Mar. 2024 was €18.96 Mil.

Aadi Bioscience's quarterly Total Liabilities increased from Sep. 2023 (€20.11 Mil) to Dec. 2023 (€24.97 Mil) but then declined from Dec. 2023 (€24.97 Mil) to Mar. 2024 (€18.96 Mil).

Aadi Bioscience's annual Total Liabilities increased from Dec. 2021 (€19.03 Mil) to Dec. 2022 (€24.41 Mil) and increased from Dec. 2022 (€24.41 Mil) to Dec. 2023 (€24.97 Mil).

Aadi Bioscience Total Liabilities Historical Data

The historical data trend for Aadi Bioscience's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aadi Bioscience Total Liabilities Chart

Aadi Bioscience Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Total Liabilities

25.69

19.03

24.41

24.97

Aadi Bioscience Quarterly Data
	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Total Liabilities	Get a 7-Day Free Trial										23.04	18.28	20.11	24.97	18.96

Aadi Bioscience Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Aadi Bioscience's Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	24.204	+	(0.764	+	-6.6613381477509E-16
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	24.97

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	121.432	-	96.464
	=	24.97

Aadi Bioscience's Total Liabilities for the quarter that ended in Mar. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	18.285	+	(0.679	+	-1.5543122344752E-15
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	18.96

Total Liabilities	=	Total Assets (Q: Mar. 2024 )	-	Total Equity (Q: Mar. 2024 )
	=	102.187	-	83.223
	=	18.96

Aadi Bioscience Total Liabilities Related Terms

Thank you for viewing the detailed overview of Aadi Bioscience's Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

Aadi Bioscience (FRA:3350) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aadi Bioscience Inc (FRA:3350) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

AADI:USA 3350:Germany

Address

17383 Sunset Boulevard, Suite A250, Pacific Palisades, CA, USA, 90272

Website

https://www.aadibio.com

Aadi Bioscience Inc is a clinical-stage biopharmaceutical company developing precision therapies for genetically-defined cancers. Aadi's primary goal is to bring transformational therapies to cancer patients with mTOR pathway driver alterations such as alterations in TSC1 or TSC2 genes, where other mTOR inhibitors have not or cannot be effectively exploited due to problems of pharmacology, effective drug delivery, safety, or effective targeting to the disease site. It has one operating segment, which is the business of developing and commercializing proprietary therapeutic. Geographically, it is located in the United States.

Aadi Bioscience (FRA:3350) Headlines

No Headlines